FDA advisors must disclose their financial ties and business relationships when serving on panels that help decide the fate of new medical devices and drugs.
FDA consultants must make new efforts to disclose their business relationships before serving on advisory panels that help determine whether a new medical device or drug gains access to the U.S. market.
The federal watchdog agency this week put the final touches on new guidance that requires a pair of new forms from prospective advisory panelists.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1jKgKFG
Cap comentari:
Publica un comentari a l'entrada